Alexion Pharmaceuticals

Contact Us Legal Sitemap

Soliris® and PNH

Alexion Pharmaceuticals is dedicated to the development of therapies that address severe, ultra-rare and life-threatening diseases, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders.

Soliris® (eculizumab), the company's first product, is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH)1, a progressive and life-threatening disease characterized by the excessive destruction of red blood cells (hemolysis).2,3 Soliris is the only treatment for PNH that reduces hemolysis.1



IMPORTANT SAFETY INFORMATION

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

Soliris® increases the risk of meningococcal infections

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full Prescribing Information and Important Safety Information for Soliris® (eculizumab).